Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk comman

Apella Capital LLC lifted its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 159.

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Bristol Myers Squibb maintains a robust portfolio in oncology and hematology with a focus on special

Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right co

Bristol Myers Squibb & Co. (NYSE:BMY) announced topline results from its Phase 3 EXCALIBER-RRMM stud

Bristol Myers Squibb reports positive Phase 3 trial data, showing ZENBEXUS cuts the multiple myeloma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Myeloma--Bristol Myers Squibb Announces ZENBEXUSTM (iberd

Cantor Fitzgerald analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral a

Bristol-Myers Squibb is reiterated as a buy, offering attractive valuation and a high 4.23% dividend

Bristol Myers Squibb is a pharmaceutical giant with a 100-year history and a 4.2% yield. Realty Inco

Reblozyl's strong growth is helping Bristol Myers offset declining legacy drug sales, with new indic

Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS serv

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight

A fat dividend yield means nothing if the cash runs dry before the check clears. These five companie

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

Dollar General, Bristol-Myers and Equinor stand out after broker rating upgrades, backed by projecte

Leerink Partners analyst David Risinger downgrades Bristol-Myers Squibb (NYSE:BMY) from Outperfor

There are blazing deals for some of the top healthcare stocks -- companies with proven track records

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 b

William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radio

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Bristol Myers Squibb (BMY) 2-year Phase 3 data shows Sotyktu maintains durable efficacy and safety i

These data are being presented at the Congress of Clinical Rheumatology - West (CCR-West) in Hunting

Piper Sandler analyst David Amsellem reiterates Bristol-Myers Squibb (NYSE:BMY) with a Overweight

HSBC analyst Rajesh Kumar maintains Bristol-Myers Squibb (NYSE:BMY) with a Hold and raises the pr

Bristol Myers Squibb reported positive Phase 2 results for its arlo-cel therapy, meeting key endpoin

Trial met primary endpoint of overall response rate and key secondary endpoint of complete response

Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effect

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Bristol Myers Squibb (NYSE:BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE

Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector.

Bristol Myers Squibb secures FDA approval for Zenbexus (iberdomide), marking the first CELMoD therap

Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has

In the complaint, the Company requests, among other things: a judgment declaring that the Company do

Vinod Khosla says AI is revolutionizing drug discovery, but drug testing needs to catch up with more

China’s science surge is reshaping global drug development as Washington moves to counter Beijing’s

During market turbulence, investors turn to dividend-yielding stocks. Benzinga provides analyst rati

New State-of-the-Art Facility Will Create Nearly 500 Skilled Jobs and Accelerate the Delivery of Nex

FDA grants Replimune accelerated approval for TUDRIQEV in combination with nivolumab to treat advanc

Argus Research analyst Jasper Hellweg upgrades Bristol-Myers Squibb (NYSE:BMY) from Hold to Buy a

Citigroup analyst Geoff Meacham maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and rais

AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation

Crude tumbles nearly 6% after Trump cancels a strike on Iran, lifting the S&P 500 1.3% and the R

Falling Oil Please click here for an enlarged chart of United States Oil ETF (NYSE:USO). N

Bristol Myers Squibb and AstraZeneca in talks for a $400B mega-merger, potentially creating the worl

Jim Cramer senses a 'fake out' in the rumored $400B AstraZeneca and Bristol Myers Squibb meg